CareDx announces district court upholds March 2022 jury verdict against Natera

CareDx (CDNA) announced that the United States District Court for the District of Delaware decision upheld and reaffirmed the March 2022 jury verdict finding that Natera (NTRA) violated the Lanham Act by falsely advertising the scientific performance of its Prospera transplant test. At the conclusion of the March 2022 trial, the jury found that Natera intentionally and recklessly misled the transplant community by deliberately engaging in false advertising in the promotion and marketing of its Prospera kidney transplant rejection assessment test. On July 17, the District Court upheld the jury’s prior decision on all of the nine counts, and where the jury found that Natera made false advertising claims about its Prospera kidney transplant test and false advertising comparisons to CareDx’s AlloSure Kidney.